Allergan Logo

Patrick Cey, Specialty Account Manager

With a heritage of almost 70 years in discovering and developing new therapeutic agents to protect and preserve vision, eye care professionals and patients rely on Allergan products to treat a variety of eye conditions. Our robust research and development investment upholds our unwavering commitment to advancing eye care treatments. Unfortunately , the prevalence of eye diseases is increasing as the population ages. Over the next decade, major progress will be made in treating such diseases and Allergan, an AbbVie company, expects to be at the forefront of these advances.



Combigan (brimonidine tartrate 0.2%/ Timolol maleate as timolol 0.5%) opthalmic solution is indicated for the control of intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension who are insufficiently responsive to IOP reducing monotherapy AND when the use of COMBIGAN is considered appropiate


Lumigan RC

Lumigan RC (bimatoprost opthalmic solution 0.01%) is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or Ocular hypertension.



RESTASIS (cyclosporine) opthalmic emulsion, 0.05% w/v is indicated for the treatment of moderate to moderately severe (Level 2-3 severity by DEWS Guidelines) aqueous deficient dry eye disease, characterized by moderate to moderately severe: ocular staining, reduction in tear production and fluctuating visual symptoms, such as blurred vision. This indication is based on a pooled analysis of a sub p...[more]

Lumigan RC Mechanism of Action

In this video you will see how Prostamides (Lumigan RC) differ from Prostaglandins.

  • The importance of IOP
  • A meta-analysis of Bimatoprost efficacy
  • Restasis patients are highly satisfied
  • Allergan, An AbbVie company helps patients with cost savings